Riskpilot← Back to searchSign inGet full accessRHINOPHARMA AS
ASActiveOrg 979652461Karihaugveien 89, 1086 OsloDental practice care activities · NACE 8623Est. 19980 employees
Revenue 2024
NOK 0
EBITDA margin
—
-3% vs 2023
Equity ratio
-134298.9%
Financial strength
Net profit 2024
NOK -19K
-4% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -19K | -3% |
| Net profit | NOK -19K | -4% |
| Total assets | NOK 2K | +304% |
| Equity | NOK -2,7M | -1% |
| Employees | 0 | — |
Legal name
RHINOPHARMA AS
Org number
979652461
Legal form
Aksjeselskap
NACE code
8623 · Dental practice care activities
Founded
9. januar 1998
Share capital
NOK 712 750
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Address
Karihaugveien 89, 1086 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | 0 | −72 | −71 | −64 | −59 | −75 | −19 | −15 | −16 | −15 | −20 | −22 | −20 | −21 | −18 | −12 | −19 | −19 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | 0 | −72 | −71 | −64 | −59 | −75 | −19 | −15 | −16 | −15 | −20 | −22 | −20 | −21 | −18 | −12 | −19 | −19 |
| Net financials | 0 | −72 | −93 | −98 | −58 | −61 | −0 | 0 | 0 | −0 | −0 | −0 | −0 | −0 | 0 | −0 | 0 | −0 |
| Profit before tax | 0 | −144 | −164 | −162 | −117 | −135 | −19 | −15 | −16 | −15 | −20 | −22 | −20 | −21 | −18 | −12 | −19 | −19 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | 0 | −144 | −164 | −162 | −117 | −135 | −19 | −15 | −16 | −15 | −20 | −22 | −20 | −21 | −18 | −12 | −19 | −19 |
| Item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | — | 6 | 1 | 1 | 0 | 2 | 0 | 1 | 0 | 2 | 1 | 4 | 0 | −0 | 1 | 7 | 0 | 2 |
| Equity | — | −1 879 | −2 042 | −2 204 | −2 321 | −2 457 | −2 476 | −2 491 | −2 507 | −2 523 | −2 543 | −2 565 | −2 585 | −2 606 | −2 624 | −2 636 | −2 655 | −2 674 |
| Long-term debt | 0 | 0 | 0 | 0 | 2 119 | 2 179 | 2 184 | 2 184 | 2 184 | 2 184 | 2 538 | 2 555 | 2 238 | 2 238 | 2 238 | 2 238 | 2 236 | 2 235 |
| Short-term debt | 0 | 25 | 90 | 155 | 203 | 279 | 292 | 307 | 323 | 340 | 6 | 14 | 347 | 368 | 387 | 404 | 419 | 441 |
| Total debt | 0 | 1 885 | 2 043 | 2 206 | 2 322 | 2 459 | 2 477 | 2 492 | 2 507 | 2 525 | 2 544 | 2 569 | 2 585 | 2 606 | 2 625 | 2 643 | 2 655 | 2 676 |
EBITDA margin
-1924700.0%
This company
15.8%
Market median
-12181746% vs market
20072024
Equity ratio
-134298.9%
This company
38.2%
Market median
-351668% vs market
20072024
Return on equity
-1929600.0%
This company
18.4%
Market median
-10487057% vs market
20072024
Net profit margin
-1929600.0%
This company
8.1%
Market median
-23822322% vs market
20072024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20072024
Debt / equity
1.00×
This company
0.62×
Market median
-61% vs market
20072024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
- Annual report 2007Filed via Brønnøysundsregistrene · Period 2007-01-01 – 2007-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
DH Chief Executive Officer | Chief Executive Officer | 2000 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2005 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Triumvare Cum Dividare As | Company | 27.7% | 27.7% | 2022 |
Diomedes As | Company | 19.1% | 19.1% | 2022 |
Health Unique Group As | Company | 18.8% | 18.8% | 2022 |
Mnm Capital As | Company | 16.1% | 16.1% | 2022 |
Ulle Holding As | Company | 10.9% | 10.9% | 2022 |
| Individual | 6.3% | 6.3% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Diomedes As
RHINOPHARMA AS Board members of RHINOPHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Dag Hovland | Chief Executive Officer | 0 companies |
| Frank Hugo Storelv | Chairman | 0 companies |